A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

References

• Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390(10110):2383–2396. doi:10.1016/s0140-6736(17)31462-9
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi V. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 2020;13(6):1010–1021. doi:10.1007/s12328-020-01237-x
   PubMed Web of Science ®Google Scholar
• Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(7):855–883. doi:10.6004/jnccn.2019.0033
   PubMed Web of Science ®Google Scholar
• Hou S, Pan Z, Hao X, Hang Q, Ding Y. Recent progress in the neoadjuvant treatment strategy for locally advanced esophageal cancer. Cancers. 2021;13(20):5162. doi:10.3390/cancers13205162
   PubMedGoogle Scholar
• Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. JAMA Surg. 2021;156(8):721–729. doi:10.1001/jamasurg.2021.2373
   PubMed Web of Science ®Google Scholar
• Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36(27):2796–2803. doi:10.1200/jco.2018.79.1483
   PubMed Web of Science ®Google Scholar
• Wang H, Tang H, Fang Y, et al. Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized clinical trial. JAMA Surg. 2021;156(5):444–451. doi:10.1001/jamasurg.2021.0133
   PubMed Web of Science ®Google Scholar
• Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–462. doi:10.1056/NEJMoa2111380
   PubMed Web of Science ®Google Scholar
• Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916–925. doi:10.1001/jama.2021.12836
   PubMed Web of Science ®Google Scholar
• Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (Jupiter-06): a multi-center Phase 3 trial. Cancer Cell. 2022;40(3):277–288.e3. doi:10.1016/j.ccell.2022.02.007
   PubMed Web of Science ®Google Scholar
• Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377:e068714. doi:10.1136/bmj-2021-068714
   PubMedGoogle Scholar
• Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–771. doi:10.1016/s0140-6736(21)01234-4
   PubMed Web of Science ®Google Scholar
• Wu Z, Zheng Q, Chen H, et al. Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. J Thorac Dis. 2021;13(6):3518–3528. doi:10.21037/jtd-21-340
   PubMed Web of Science ®Google Scholar
• Liu J, Yang Y, Liu Z, et al. Multicenter, single-arm, Phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10(3). doi:10.1136/jitc-2021-004291
   Google Scholar
• Liu J, Li J, Lin W, et al. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, Phase 2 study. Int J Cancer. 2022;151(1):128–137. doi:10.1002/ijc.33976
   PubMedGoogle Scholar
• Xing W, Zhao L, Zheng Y, et al. The sequence of chemotherapy and toripalimab might influence the efficacy of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell cancer-a phase II study. Front Immunol. 2021;12:772450. doi:10.3389/fimmu.2021.772450
   PubMed Web of Science ®Google Scholar
• Deng H, Zhao Y, Cai X, et al. PD-L1 expression and tumor mutation burden as pathological response biomarkers of neoadjuvant immunotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;170:103582. doi:10.1016/j.critrevonc.2022.103582
   PubMed Web of Science ®Google Scholar
• Lefler DS, Snook AE, Bashir B. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1. Immunotherapy. 2022;14(11):885–902. doi:10.2217/imt-2022-0012
   PubMed Web of Science ®Google Scholar
• Li Q, Zhou S, Liu S, et al. Treatment-related lymphopenia predicts pathologic complete response and recurrence in esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2019;26(9):2882–2889. doi:10.1245/s10434-019-07334-7
   PubMedGoogle Scholar
• Wu Y, Chen J, Zhao L, et al. Prediction of pathologic response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma incorporating hematological biomarkers. Cancer Res Treat. 2021;53(1):172–183. doi:10.4143/crt.2020.594
   PubMed Web of Science ®Google Scholar
• Li C, Lin JW, Yeh HL, Chuang CY, Chen CC. Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism. Sci Rep. 2021;11(1):11626. doi:10.1038/s41598-021-90753-y
   PubMedGoogle Scholar
• Cai G, Yu J, Meng X. Predicting prognosis and adverse events by hematologic markers in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. Cancer Manag Res. 2020;12:8497–8507. doi:10.2147/cmar.S257058
   PubMed Web of Science ®Google Scholar
• Feng J, Wang L, Yang X, Chen Q, Cheng X. Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: a real-world study. Bosn J Basic Med Sci. 2022. doi:10.17305/bjbms.2022.7696
   Google Scholar
• Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119–130. doi:10.21037/acs.2017.03.14
   PubMed Web of Science ®Google Scholar
• Zinellu A, Collu C, Nasser M, et al. The Aggregate Index of Systemic Inflammation (AISI): a novel prognostic biomarker in idiopathic pulmonary fibrosis. J Clin Med. 2021;10(18):4134. doi:10.3390/jcm10184134
   PubMed Web of Science ®Google Scholar
• Li X, Zhang S, Lu J, Li C, Li N. The prognostic value of systemic immune-inflammation index in surgical esophageal cancer patients: an updated meta-analysis. Front Surg. 2022;9:922595. doi:10.3389/fsurg.2022.922595
   PubMed Web of Science ®Google Scholar
• Budczies J, Klauschen F, Sinn BV, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7(12):e51862. doi:10.1371/journal.pone.0051862
   PubMed Web of Science ®Google Scholar
• Shao Y, Lin S, Zhang P, et al. Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers. Biosci Rep. 2021;41(1). doi:10.1042/bsr20202613
   Google Scholar
• Wang L, Simons DL, Lu X, et al. Breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes. EBioMedicine. 2020;52:102631. doi:10.1016/j.ebiom.2020.102631
   PubMedGoogle Scholar
• Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. J Leukoc Biol. 2019;106(2):309–322. doi:10.1002/jlb.4ri0818-311r
   PubMed Web of Science ®Google Scholar
• Zhao H, Chen W, Wu J, Wang L, Mao W. Clinical significance of preoperative serum tumor markers in esophageal squamous cell carcinoma. J Cancer Res Ther. 2014;10(Suppl):C179–85. doi:10.4103/0973-1482.145863
   PubMedGoogle Scholar
• Hong Z, Huang Z, Chen Z, Kang M. Prognostic value of carcinoembryonic antigen changes before and after operation for esophageal squamous cell carcinoma. World J Surg. 2022;46(11):2725–2732. doi:10.1007/s00268-022-06672-0
   PubMedGoogle Scholar
• Yang Y, Huang X, Zhou L, et al. Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma. BMC Cancer. 2019;19(1):526. doi:10.1186/s12885-019-5755-5
   PubMedGoogle Scholar
• Li ZC, Sun YT, Lai MY, Zhou YX, Qiu MZ. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: a systematic review and network meta-analysis. Int Immunopharmacol. 2022;109:108790. doi:10.1016/j.intimp.2022.108790
   PubMed Web of Science ®Google Scholar
• Zhu X, Shanzhou Q, Li D, Pang X, Ma D. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis. BMC Cancer. 2021;21(1):1195. doi:10.1186/s12885-021-08958-3
   PubMedGoogle Scholar
• Shen D, Chen Q, Wu J, Li J, Tao K, Jiang Y. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma. J Gastrointest Oncol. 2021;12(1):1–10. doi:10.21037/jgo-20-599
   PubMed Web of Science ®Google Scholar
• Yang P, Zhou X, Yang X, et al. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study. World J Surg Oncol. 2021;19(1):333. doi:10.1186/s12957-021-02446-5
   PubMed Web of Science ®Google Scholar
• Lv H, Tian Y, Li J, et al. Neoadjuvant sintilimab plus chemotherapy in resectable locally advanced esophageal squamous cell carcinoma. Front Oncol. 2022;12:864533. doi:10.3389/fonc.2022.864533
   PubMedGoogle Scholar
• Feng J, Wang L, Yang X, Chen Q, Cheng X. Pathologic complete response prediction to neoadjuvant immunotherapy combined with chemotherapy in resectable locally advanced esophageal squamous cell carcinoma: real-world evidence from integrative inflammatory and nutritional scores. J Inflamm Res. 2022;15:3783–3796. doi:10.2147/jir.S367964
   PubMed Web of Science ®Google Scholar
• Zhang X, Gari A, Li M, et al. Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma. J Transl Med. 2022;20(1):61. doi:10.1186/s12967-022-03252-7
   PubMed Web of Science ®Google Scholar
• Deng H, Liang H, Chen J, et al. Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers. Transl Lung Cancer Res. 2022;11(12):2364–2381. doi:10.21037/tlcr-22-439
   PubMedGoogle Scholar
• Qiu F, Fan J, Shao M, et al.Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): a randomized, single center, two-arm phase II trial. ASCO Annual Meeting. 2022;2022. doi:10.1200/JCO.2022.40.16_suppl.8500
   Google Scholar